We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Contraceptive Device Cleared by FDA

By HospiMedica staff writers
Posted on 09 Jan 2001
A small, flexible T-shaped contraceptive device has been cleared by the U.S. More...
Food and Drug Administration (FDA). Called Mirena, the device is intended for women who prefer a long-acting but reversible contraceptive.

Mirena is inserted into the uterus by a doctor in just a few minutes. It does not contain estrogen. Instead, it releases a low dose of progestin. The device is as effective as tubal ligation (99%) and lasts for five years or until removed. Use of the device may make menstrual periods shorter and lighter.

Mirena has been used in Europe for the past 10 years. Currently, about 80% of U.S. women between 18 and 49 who use long-acting contraception choose sterilization, which is typically not reversible. After the removal of Mirena, a woman's fertility returns rapidly.
The device does not protect against HIV and other sexually transmitted diseases.

Use of intrauterine devices (IUDs) has been associated with an increased risk of pelvic inflammatory disease (PID). The highest risk of PID occurs shortly after insertion. A decision to use Mirena must include consideration of the risks of PID, say doctors. Women who use the device should have no history of ectopic pregnancy or a condition that would predispose to ectopic pregnancy. Mirena is marketed outside the United States by Schering AG (Berlin, Germany).



Related Links:
Schering

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Surgical Headlight
IsoTorch
ow Frequency Pulse Massager
ET10 L
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.